Key facts
- This page summarizes Fuad El-Hibri's Form 4 filing for Emergent BioSolutions Inc. (EBS).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 07 Dec 2021, 20:10.
Fuad El-Hibri - 03 Dec 2021 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)
- Reporting relationship
- Director
- Issuer ticker
- EBS
- Reported as of
- 03 Dec 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Dec 2021, 20:10:11 UTC
- Prior SEC filing
- 02 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carl A. Valenstein, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Fuad El-Hibri filed Form 4 for Emergent BioSolutions Inc. (EBS) on 07 Dec 2021.
Change
- Previous filing in this sequence was filed on 02 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EBS
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- +3,018,644
- Change %
- Price
- $0.000000
- Shares after
- 3,018,644
- Date
- 03 Dec 2021
- Ownership
- See Footnote
- Footnotes
- F1, F2
EBS
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- +274,930
- Change %
- Price
- $0.000000
- Shares after
- 274,930
- Date
- 03 Dec 2021
- Ownership
- See Footnote
- Footnotes
- F1, F3
EBS
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- +206,434
- Change %
- Price
- $0.000000
- Shares after
- 206,434
- Date
- 03 Dec 2021
- Ownership
- See Footnote
- Footnotes
- F1, F4
EBS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,136,971
- Date
- 03 Dec 2021
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
On December 3, 2021, each of Intervac L.L.C., a Maryland limited liability company ("Intervac"), and BioVac, L.L.C., a Maryland limited liability company ("BioVac"), effected a pro-rata liquidating distribution to their respective members of shares of the Issuer's common stock for no consideration (the "Distribution"). In prior reports filed by the reporting person pursuant to Section 16, the reporting person reported indirect beneficial ownership over shares of the Issuer's common stock held by Intervac and BioVac. After giving effect to the Distribution, the reporting person no longer has beneficial ownership over 164,610 shares of the Issuer's common stock that was previously reported as beneficially owned by BioVac.
Footnote F2
Held by the Yahia Fuad El-Hibri Revocable Trust, for which the reporting person serves as the Trustee. Comprised of (i) 1,659,099 shares of the Issuer's common stock previously reported as beneficially owned by Intervac and (ii) 1,359,545 shares of the Issuer's common stock previously reported as beneficially owned by BioVac. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the Yahia Fuad El-Hibri Revocable Trust except to the extent of his pecuniary interest therein.
Footnote F3
Held by the El-Hibri Family Trust, for which the reporting person's wife serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El Hibri Family Trust except to the extent of his pecuniary interest therein.
Footnote F4
Held by the El-Hibri Decedents Trust, for which the reporting person serves as the Trustee. The reporting person expressly disclaims beneficial ownership of any shares of the Issuer's common stock owned by the El-Hibri Decendents Trust except to the extent of his pecuniary interest therein.